Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.

NCT Number	NCT07358806
Lead Sponsor	Oscotec Inc.
Conditions	Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric/Gastroesophageal Junction Cancer
Enrollment	51 participants
Start Date	2025-12-18
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-22